{
  "ticker": "LLY",
  "target_date": "2024-12-24",
  "actual_date": "2024-12-24",
  "collected_at": "2025-12-08T11:11:16.707402",
  "price": {
    "open": 785.51,
    "high": 791.84,
    "low": 781.27,
    "close": 789.7791137695312,
    "volume": 1165400,
    "change_1d_pct": -0.08,
    "change_7d_pct": 0.83,
    "change_30d_pct": -4.26
  },
  "technicals": {
    "rsi_14": 36.59,
    "sma_20": 788.04,
    "sma_50": 809.65,
    "macd": -7.86,
    "macd_signal": -9.471,
    "macd_histogram": 1.611,
    "bb_upper": 827.35,
    "bb_lower": 748.73,
    "price_vs_sma20_pct": 0.22,
    "price_vs_sma50_pct": -2.45,
    "volume_ratio": 0.33
  },
  "fundamentals": {
    "market_cap": 890522238976,
    "pe_ratio": 48.67124,
    "forward_pe": 43.83848,
    "price_to_book": 37.401356,
    "price_to_sales": 14.986961,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.67,
    "pct_from_52w_low": 59.25
  },
  "macro": {
    "spy": {
      "price": 596.08,
      "change_1d_pct": 1.11,
      "change_7d_pct": -0.57
    },
    "vix": {
      "level": 14.27,
      "signal": "LOW_FEAR"
    },
    "treasury_10y": {
      "yield_pct": 4.59
    },
    "dollar_index": {
      "level": 108.26
    },
    "gold": {
      "price": 2620.0
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know",
      "source": "Yahoo",
      "datetime": 1735080320,
      "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $795.67, indicating a -0.08% shift from the previous trading day.",
      "url": "https://finnhub.io/api/news?id=c4bd767bd7c7dec61d4fbe5f1e5fe2af6ec255e1ffd8957c6b19f171d8d1deff"
    },
    {
      "headline": "What's next for GLP-1 weight-loss drugs in 2025?",
      "source": "Yahoo",
      "datetime": 1735069500,
      "summary": "GLP-1 weight-loss drugs have dominated healthcare headlines in 2024, marked by expanded employer coverage, dynamic pricing changes, and pharmaceutical giants like Novo Nordisk (NVO) and Eli Lilly (LLY) exploring broader applications beyond weight management, including heart disease and sleep apnea t",
      "url": "https://finnhub.io/api/news?id=1f029c1f3a96f8489dbc131709c904839c81db9b41de6f89c972de54abae3e79"
    },
    {
      "headline": "3 biggest catalysts expected for healthcare in 2025",
      "source": "Yahoo",
      "datetime": 1735060800,
      "summary": "After an eventful year in the pharmaceutical and biotech industries, what lies ahead for the health landscape in 2025? Yahoo Finance senior health reporter Anjalee Khemlani outlines the three biggest catalysts for change and innovation for healthcare in the new year, including GLP-1 weight-loss drug",
      "url": "https://finnhub.io/api/news?id=d257b317d5d05997105840bc14ccb6a93eae24c968c53d9f1a66458a6df399af"
    },
    {
      "headline": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors",
      "source": "MarketWatch",
      "datetime": 1735057980,
      "summary": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=6eb528bd927c1a7302bc1a734dfeee87d3041524b8b16ded8d0c69b028e22979"
    },
    {
      "headline": "Retail investors buy Novo dip after disappointing weight-loss drug data",
      "source": "Yahoo",
      "datetime": 1735051107,
      "summary": "U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected obesity drug data offered a rare dip-buying opportunity, according to Vanda Research.  Daily net flows climbed to $15.6 million from $0.49 million a day earlier, after eagerly a",
      "url": "https://finnhub.io/api/news?id=51043bbf8ece511da1188efaa73a21755ab63c32c79cae5bf2dd392df87306db"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470584.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000291/xslF345X05/wk-form4_1734470584.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470498.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000289/xslF345X05/wk-form4_1734470498.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470366.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000287/xslF345X05/wk-form4_1734470366.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470270.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000285/xslF345X05/wk-form4_1734470270.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470180.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000283/xslF345X05/wk-form4_1734470180.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}